FMOC‐ASP‐ODMAB
|
|
|
- CAS番号.
- 172611-77-7
- 化学名:
- FMOC‐ASP‐ODMAB
- 别名:
- FMOC‐ASP‐ODMAB;N-(9H-フルオレン-9-イルメトキシカルボニル)-L-アスパラギン酸1-[4-[1-[2,6-ジオキソ-4,4-ジメチルシクロヘキシリデン]-3-メチルブチルアミノ]ベンジル];(3S)-4-[(4-{[1-(4,4-ジメチル-2,6-ジオキソシクロヘキシリデン)-3-メチルブチル]アミノ}フェニル)メトキシ]-3-({[(9H-フルオレン-9-イル)メトキシ]カルボニル}アミノ)-4-オキソブタン酸;Fmoc-Asp-ODmab
- 英語名:
- FMOC-ASP-ODMAB
- 英語别名:
- FMOC-ASP-ODMAB;Fmoc-L-Asp-ODmab;FMOC-ASP-ODMAB 5 G;(9H-Fluoren-9-yl)MethOxy]Carbonyl Asp-ODmab;Fmoc-L-aspartic acid α-4-[N-{1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl}amino]benzyl ester;Fmoc-L-aspartic acid alpha-4-[N-{1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl}amino]benzyl ester;FMOC-L-ASPARTIC ACID ALPHA-4-[N-[1-(4,4-DIMETHYL-2,6-DIOXOCYCLOHEXYLIDENE)-3-METHYLBUTYL]AMINO]BENZYL ESTER;N-ALPHA-FMOC-L-ASPARTIC ACID ALPHA-4-[N-[1-(4,4-DIMETHYL-2,6-DIOXOCYCLOHEXYLIDENE)-3-METHYLBUTYL]-AMINO] BENZYL ESTER;N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-aspartic acid 1-[[4-[[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]amino]phenyl]methyl] ester;L-Aspartic acid, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-, 1-[[4-[[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]amino]phenyl]methyl] ester
- CBNumber:
- CB2713809
- 化学式:
- C39H42N2O8
- 分子量:
- 666.76
- MOL File:
- Mol file
|
FMOC‐ASP‐ODMAB 物理性質
- 沸点 :
- 838.4±65.0 °C(Predicted)
- 比重(密度) :
- 1.264±0.06 g/cm3(Predicted)
- 貯蔵温度 :
- Store at -15°C to -25°C.
- 酸解離定数(Pka):
- 4.01±0.19(Predicted)
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
| 絵表示（GHS） |
|
| 注意喚起語 |
警告 |
| 危険有害性情報 |
| コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
| H302 |
飲み込むと有害 |
急性毒性、経口 |
4 |
警告 |
|
P264, P270, P301+P312, P330, P501 |
| H315 |
皮膚刺激 |
皮膚腐食性/刺激性 |
2 |
警告 |
|
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
強い眼刺激 |
眼に対する重篤な損傷性/眼刺激 性 |
2A |
警告 |
|
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
呼吸器への刺激のおそれ |
特定標的臓器毒性、単回暴露； 気道刺激性 |
3 |
警告 |
|
|
|
| 注意書き |
| P261 |
粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。 |
| P280 |
保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。 |
| P301+P312 |
飲み込んだ場合：気分が悪い時は医師に連絡する こと。 |
| P302+P352 |
皮膚に付着した場合：多量の水と石鹸で洗うこと。 |
| P305+P351+P338 |
眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。 |
|
FMOC‐ASP‐ODMAB 価格
もっと(1)
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
関東化学株式会社(KANTO)
|
49928-89 |
Ｆｍｏｃ‐Ａｓｐ‐ＯＤｍａｂ
Fmoc‐Asp‐ODmab |
17261-77-7 |
1g |
￥42700 |
2024-07-01 |
購入 |
FMOC‐ASP‐ODMAB 化学特性,用途語,生産方法
化学的特性
FMOC-ASP-ODMAB
is Yellow powder
使用
The Dmab group can be cleaved selectively in the presence of tBu-based protected groups by treatment with 2% hydrazine in DMF, making this derivative an extremely useful tool for the preparation of cyclic peptides by FMOC SPPS
一般的な説明
Quasi-orthogonally-protected Asp derivative.
The Dmab group can be removed selectively in the presence of tBu-based protecting groups by treatment with 2% hydrazine in DMF [1], making this derivative an extremely useful tool for the preparation of cyclic peptides by Fmoc SPPS or for library synthesis.
Occasionally sluggish cleavage of the aminobenzyl moiety is observed [2, 3]. In these instances, washing the support with 20% DIPEA in DMF/water (9:1) [2] or HCl in dioxane [4] has been found to be efficacious.
For the on-resin synthesis of side-chain to side-chain lactam bridged peptides, the combination of Lys(ivDde) and Asp(ODmab) is particularly advantageous since both side-chains can be simultaneously unmasked in a single step.
To avoid aspartimide formation, it is advisable to employ an Hmb- or Dmb-protected derivative for introduction of the preceding residue.
For applications of this derivative in the synthesis of cyclic peptides, see references [5 - 7].
The product number for this product was previously 04-12-1176.
To obtain a certificate of analysis (CoA) of a lot that begins with the letter “A”, please select the option in the right hand menu “Request a COA for Lot#s starting with A”.
FMOC‐ASP‐ODMAB 上流と下流の製品情報
原材料
準備製品
FMOC‐ASP‐ODMAB 生産企業
Global( 46)Suppliers
172611-77-7(FMOC‐ASP‐ODMAB)キーワード:
- 172611-77-7
- (S)-3-(((9H-fluoren-9-yl)methyl9H-fluoren-9-yl)methoxy)carbonylamino)-4-(4-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutylamino)benzyloxy)-4-oxobutanoic acid
- Fmoc-L-aspartic acid alpha-4-[N-{1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl}amino]benzyl ester
- N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-aspartic acid 1-[[4-[[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]amino]phenyl]methyl] ester
- Fmoc-L-Asp-ODmab
- N-ALPHA-FMOC-L-ASPARTIC ACID ALPHA-4-[N-[1-(4,4-DIMETHYL-2,6-DIOXOCYCLOHEXYLIDENE)-3-METHYLBUTYL]-AMINO] BENZYL ESTER
- FMOC-L-ASPARTIC ACID ALPHA-4-[N-[1-(4,4-DIMETHYL-2,6-DIOXOCYCLOHEXYLIDENE)-3-METHYLBUTYL]AMINO]BENZYL ESTER
- FMOC-ASP-ODMAB
- (3S)-4-[(4-{[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]amino}phenyl)methoxy]-3-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-4-oxobutanoic acid
- (9H-Fluoren-9-yl)MethOxy]Carbonyl Asp-ODmab
- FMOC-ASP-ODMAB 5 G
- Fmoc-L-aspartic acid α-4-[N-{1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl}amino]benzyl ester
- (S)-3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-((4-((1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl)amino)benzyl)oxy)-4-oxobutanoic acid
- L-Aspartic acid, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-, 1-[[4-[[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]amino]phenyl]methyl] ester
- FMOC‐ASP‐ODMAB
- N-(9H-フルオレン-9-イルメトキシカルボニル)-L-アスパラギン酸1-[4-[1-[2,6-ジオキソ-4,4-ジメチルシクロヘキシリデン]-3-メチルブチルアミノ]ベンジル]
- (3S)-4-[(4-{[1-(4,4-ジメチル-2,6-ジオキソシクロヘキシリデン)-3-メチルブチル]アミノ}フェニル)メトキシ]-3-({[(9H-フルオレン-9-イル)メトキシ]カルボニル}アミノ)-4-オキソブタン酸
- Fmoc-Asp-ODmab